Pharma News
Cuba strengthens biotech industry through Eurasian partnerships
Cuba is consolidating its position in the field of biotechnology thanks to cooperation with several Eurasian nations, in particular Russia and Belarus.
Biosimilars manufacturing facilities approved by EU and US
Two biological drugs manufacturing facilities for biosimilar epoetin alfa and biosimilar bevacizumab were approved in the US and Europe in May and April 2023, respectively.
Cuba and China strengthen scientific cooperation for the development of medical treatments
In recent years, Cuba and China have established agreements to develop innovative medical treatments, notably Center for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología, CIGB) and Center for Molecular Immunology (Centro de Inmunología Molecular, CIM), and have shared their experiences in the field of medical research.
HK inno.N–mAbxience partnership in Korea and Coherus advances in the US
In early 2023, it was announced that South Korea’s HK inno.N signed an exclusive license agreement with Spain's mAbxience to bring a denosumab biosimilar to market in South Korea. In addition, in the US, Coherus BioSciences is to acquire exclusive commercial rights to Formycon’s under-development Eylea (aflibercept) biosimilar.
Global marketing and commercialization advances for Alvotech and partners
In late 2022 and early 2023, Alvotech announced several strategic partnership advances to further their global reach as a biotech company specializing in the development and manufacture of biosimilar medicines.
New partnerships: Biocon-Yoshindo and Syna-Intas
Biocon Biologics announced on 17 October 2022 that it has entered into a strategic out-licensing agreement with Japanese pharmaceuticals company Yoshindo for commercializing two of its pipeline biosimilar assets in Japan. Following this, on 2 November 2022, Syna Therapeutics signed an exclusive license agreement with Intas to commercialize a haematology biosimilar.
New funding to strengthen Cuba's biopharmaceutical industry
On 22 September 2022, the United Nations Development Programme (UNDP) announced the execution of a loan of Euros 46.7 million (US$45.25 million dollars) to support Cuba's biopharmaceutical industry and improve the country's capacity to respond against diseases such as COVID-19.
Similis-Blau biosimilars development partnership announced
On 25 October 2022, JSR Life Sciences (and LLC (JSR)) have announced that their recently launched biosimilars development branch, Similis Bio, has signed a development and license agreement with Brazilian firm, Blau Farmacêutica.
GaBI news digest for 14 October 2022
Selected news for the week of 14 October 2022 for GaBI readers.
FDA inspections in Iceland and Singapore for Alvotech and Strides
On 5 September 2022, Alvotech announced that it had received communication from the US Food and Drug Administration (FDA) that detailed the assessment of their Icelandic manufacturing facility and Alvotech’s subsequent written responses to FDA. This followed Strides announced the successful FDA inspection of their Singapore facility in early August 2022.
